Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Ibrutinib and Rituximab for cGVHD
NCT03689894Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Apr 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Dartmouth Health. Primary endpoint: Dose-limiting Toxicities at 4 weeks. Started Apr 2019; status: terminated.
02
Drugs
ibrutinibrituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03689894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689894.